RLYB vs. LPTX, MGTA, CTMX, CRDF, ELYM, ALDX, VTYX, DSGN, RANI, and ACRV
Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Leap Therapeutics (LPTX), Magenta Therapeutics (MGTA), CytomX Therapeutics (CTMX), Cardiff Oncology (CRDF), Eliem Therapeutics (ELYM), Aldeyra Therapeutics (ALDX), Ventyx Biosciences (VTYX), Design Therapeutics (DSGN), Rani Therapeutics (RANI), and Acrivon Therapeutics (ACRV). These companies are all part of the "medical" sector.
Rallybio (NASDAQ:RLYB) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment.
Rallybio has a beta of -1.65, suggesting that its share price is 265% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
Rallybio's return on equity of -66.59% beat Leap Therapeutics' return on equity.
In the previous week, Rallybio and Rallybio both had 1 articles in the media. Rallybio's average media sentiment score of 0.59 equaled Leap Therapeutics'average media sentiment score.
Rallybio has higher earnings, but lower revenue than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
Leap Therapeutics received 257 more outperform votes than Rallybio when rated by MarketBeat users. However, 73.33% of users gave Rallybio an outperform vote while only 68.72% of users gave Leap Therapeutics an outperform vote.
90.3% of Rallybio shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 7.4% of Rallybio shares are held by insiders. Comparatively, 11.3% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Rallybio presently has a consensus price target of $12.20, indicating a potential upside of 724.32%. Leap Therapeutics has a consensus price target of $11.00, indicating a potential upside of 391.07%. Given Rallybio's higher possible upside, equities research analysts clearly believe Rallybio is more favorable than Leap Therapeutics.
Summary
Rallybio beats Leap Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Rallybio News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rallybio Competitors List
Related Companies and Tools
